Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Cervical Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


7 drugs have received FDA approval for Cervical Cancer . Bevacizumab, Bleomycin Sulfate, Pembrolizumab, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine and Topotecan Hydrochloride
110 drugs have a clinical trial registered for Cervical Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 837 clinical trials for Cervical Cancer,
309 of which have one or more drug interventions,
528 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 51 Cell Line Models for Cervical Cancer.

Source: COSMIC
(see details)

Chemistry


There are 3031 Compounds which have been tested in Cervical Cancer , 1223 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Cervical Cancer:
Uterine Cervical Neoplasms

The following terms have been mapped from cancer.gov to Cervical Cancer:
Cervical cancer
Cervical cancer that has not gotten better with other treatment or has recurred (come back). It is used with another drug, called cisplatin
Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back)
Cervical cancer that is recurrent or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after chemotherapy.????
Lesions that sometimes lead to anal, cervical, vaginal, or vulvar cancer
Lesions that sometimes lead to cervical cancer
Squamous cell carcinoma of the cervix